Results 31 to 40 of about 342,150 (384)

Dental Students in Egypt: To What Extent Do They Perceive and Comply with Infection Control Measures?

Journal of Pure and Applied Microbiology, 2021
This study was carried out in the dental school of Ahram Canadian University in Egypt to investigate the knowledge and compliance of senior students and interns toward infection control practices.
Basma A. Elawady, Mona S. Mohamed, Eman H. Elsebaie, Essraa A. Hegazy, Lamiaa A. Madkour   +4 more
doaj   +1 more source

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease [PDF]

, 2015
Hepatitis B virus (HBV) infection is a dynamic state of interactions among HBV, hepatocytes, and the host immune system. Natural history studies of chronic hepatitis B (CHB) infection have shown an association between active viral replication and adverse
Farinati, Fabio, Gottardo, G, Rodr\uedguez Castro, K, Russo, FRANCESCO PAOLO, Scribano, L, Vanin, V   +5 more
core   +1 more source

MicroRNAs Associated With HBV Infection And HBV-related HCC [PDF]

Theranostics, 2014
Hepatitis B virus (HBV) infection is a global problem and a major risk factor for hepatocellular carcinoma (HCC). microRNAs (miRNAs) comprise a group of small noncoding RNAs regulating gene expression at the posttranslational level, thereby participating in fundamental biological processes, including cell proliferation, differentiation, and apoptosis ...
Xie, Kun-Lin, Zhang, Yan-Ge, Liu, Jun, Zeng, Yong, Wu, Hong   +4 more
openaire   +2 more sources

HBV-Induced Immune Imbalance in the Development of HCC

Frontiers in Immunology, 2019
Chronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC. Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation and hepatocellular regeneration account for hepatocarcinogenesis.
Yongyan Chen, Z. Tian
semanticscholar   +1 more source

Kinetics of acute hepatitis B virus infection in humans [PDF]

, 2001
Using patient data from a unique single source outbreak of hepatitis B virus (HBV) infection, we have characterized the kinetics of acute HBV infection by monitoring viral turnover in the serum during the late incubation and clinical phases of the ...
Brown, D., Dusheiko, G.M., Emery, V.C., Murray, J.M., Perelson, A.S., Webster, G.J.M., Whalley, S.A.   +6 more
core   +1 more source

Management of HBV and HBV/HDV-Associated Liver Cirrhosis [PDF]

Visceral Medicine, 2016
<b><i>Background:</i></b> Chronic hepatitis B virus (HBV) infection and hepatitis delta virus (HDV) co-infection lead to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> We review the current knowledge of the management of HBV mono-infection and HBV/HDV ...
Christoph, Höner Zu Siederdissen, Markus, Cornberg   +1 more
openaire   +2 more sources

Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with Hepatitis B virus infection [PDF]

, 2005
CD4+ CD25+ regulatory T cells have been shown to maintain peripheral tolerance against self and foreign antigens. In this study we analyzed the effect of circulating CD4+ CD25+ T cells on CD8+-T-cell responses of patients with chronic and resolved ...
Bertoletti, A., Franzese, O., Gehring, A.J., Gotto, J., Kennedy, P.T.F., Maini, M.K., Williams, R.   +6 more
core   +2 more sources

HBV virological assessment

Journal of Hepatology, 2006
Management of hepatitis B virus (HBV) infected patients involves serological diagnosis, quantitation of HBV-DNA and measurement of HBV drug resistance. Different serological markers such as HBsAg, anti-HBs, anti-HBc (total and IgM), HBeAg and anti-HBe are assessed by immunoassays in order to define the infection status. The emergence of surface mutants
Hatzakis, A, Magiorkinis, E, Haida, C
openaire   +3 more sources

Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference

Hepatology, 2019
Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to “cure” HBV ...
M. Cornberg, A. Lok, N. Terrault, F. Zoulim, T. Berg, M. Brunetto, S. Buchholz, M. Buti, H. Chan, Kyong‐Mi Chang, M. Dandri, G. Dusheiko, J. Feld, C. Ferrari, M. Ghany, H. Janssen, P. Kennedy, P. Lampertico, Jake T Liang, S. Locarnini, M. Maini, P. Mishra, G. Papatheodoridis, J. Petersen, S. Schlottmann, Su-Wen Wang, H. Wedemeyer, N. Afdhal, D. Apelian, N. Brown, M. Beumont‐Mauviel, G. Cloherty, M. Cornberg, T. Dickens, Eric F. Donaldson, A. Gaggar, B. Given, U. Lopatin, A. Lok, V. Miller, G. Picchio, P. Revill, N. Terrault, A. Vaillant, L. Vernoux, C. Wat, J. Young, F. Zoulim   +47 more
semanticscholar   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source